Northern Trust Corp Acquires 24,452 Shares of InspireMD, Inc. (NYSE:NSPR)

Northern Trust Corp grew its holdings in InspireMD, Inc. (NYSE:NSPR) by 103.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,022 shares of the company’s stock after purchasing an additional 24,452 shares during the period. Northern Trust Corp owned approximately 0.18% of InspireMD worth $126,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of NSPR. Essex Investment Management Co. LLC bought a new stake in shares of InspireMD in the fourth quarter valued at approximately $191,000. Legato Capital Management LLC bought a new stake in shares of InspireMD in the fourth quarter valued at approximately $47,000. Finally, Renaissance Technologies LLC bought a new stake in shares of InspireMD in the fourth quarter valued at approximately $27,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Trading Up 0.4%

NYSE:NSPR opened at $2.55 on Wednesday. The company has a 50-day moving average price of $2.53 and a 200-day moving average price of $2.74. InspireMD, Inc. has a 12 month low of $2.07 and a 12 month high of $3.80. The stock has a market cap of $78.12 million, a price-to-earnings ratio of -3.40 and a beta of 0.62.

Analyst Ratings Changes

Several research firms have recently issued reports on NSPR. Wall Street Zen assumed coverage on shares of InspireMD in a research report on Monday, May 5th. They issued a “sell” rating on the stock. Piper Sandler cut their price target on shares of InspireMD from $4.50 to $4.00 and set an “overweight” rating for the company in a research note on Monday, May 12th.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.